

Symlin Pen® (pramlintide)
Effective 08/01/20

Plan	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Pramlintide is a synthetic analog of human amylin cosecreted with insulin by pancreatic beta cells; reduces postprandial glucose increases via the following mechanisms: 1) prolongation of gastric emptying time, 2) reduction of postprandial glucagon secretion, and 3) reduction of caloric intake through centrally-mediated appetite suppression. Pramlintide is indicated as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy.

Coverage Guidelines

Authorization may be granted for members who are currently receiving treatment with Symlin Pen, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs
Or

Authorization may be granted when all of the following criteria are met, and documentation has been provided:

1. The patient has a diagnosis of type 1 or type 2 diabetes mellitus
2. The patient is currently receiving optimal mealtime insulin therapy
3. The patient has experienced an inadequate treatment response to insulin
4. The patient does not require drug therapy to stimulate gastrointestinal motility

Continuation of Therapy

Reauthorization may be granted when a physician’s assessment has been submitted documenting the patient has had an expected reduction in HbA1c since starting Symlin therapy.

Limitations

1. Authorizations will be granted for 36 months



References

1. Symlin (pramlintide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2019
2. Galderisi A, Sherr J, VanName M, et al. Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes. *J Clin Endocrinol Metab* 2018; 103:1088
3. Inzucchi S., Buse JB, Bergenstal R, et al. Management of hyperglycemia in type 2 diabetes: A Patient-Centered Approach: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2012 Jun;35(6):1364-79. Epub 2012 Apr 19.
4. American Diabetes Association. Standards of medical care in diabetes – 2020. *Diabetes Care*. 2020;43(Suppl. 1): S1-S212.

Review History

04/2017 – Reviewed

04/17/2019 – Reviewed

05/20/2020 – Reviewed and Updated May P&T Mtg; updated overview and references; removed rationale from criteria; added started and stabilized statement. Effective 8/1/20.

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.